Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

News

Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna

byCharles Gross

February 10, 2023

1 minute read

https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna

HashKey’s New License Could Spark A Wave of Investment In Hong Kong’s Digital Asset Sector

By Murtuza Merchant

August 3, 9:26 AM

HashKey received a license under Hong Kong's new cryptocurrency regulations, marking a significant step towards legitimizing the retail trading of digital assets in the city.

$FTT

Top 5 Risk Off Stocks That May Plunge In Q2

By Lisa Levin

June 16, 7:55 AM

The most overbought stocks in the consumer staples sector presents an opportunity to go short on these overvalued companies.

COCO

News

Costco Executive Says ‘We’ve Seen Some Weakness In What I’ll Call Big Ticket Discretionary Items’

By Michael Horton

March 2, 6:37 PM

-Reuters

COST

Goldman Sachs Advances with AI for Coding and Documentation, Stresses Human Oversight in Tech Integration

By Anusuya Lahiri

November 10, 3:19 PM

Goldman Sachs Group, Inc (NYSE: GS) is actively integrating generative

Pfizer And BioNTech Begin Phase 1/2 Trial Of First-In-Class mRNA-Based Shingles Vaccine Program

Related Posts

HashKey’s New License Could Spark A Wave of Investment In Hong Kong’s Digital Asset Sector

Top 5 Risk Off Stocks That May Plunge In Q2

Costco Executive Says ‘We’ve Seen Some Weakness In What I’ll Call Big Ticket Discretionary Items’

Goldman Sachs Advances with AI for Coding and Documentation, Stresses Human Oversight in Tech Integration